Metastatic Melanoma - Provectus Adds 6th Center To Phase 2 Clinical Trial Of PV-10
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has begun recruitment for its Phase 2 clinical trial of the Company’s lead oncology agent PV-10 at a sixth major center located at the California Pacific Medical Center, in San Francisco, CA. David Minor, M.D. will serve as principal investigator at the new center covering the western United States.
Original post by Dermatology News From Medical News Today
Leave a Reply
You must be logged in to post a comment.